MAPT and Alzheimer disease: By directly comparing the levels of the tau biomarkers in plasma, we observed that p-tau217, followed by p-tau205 and p-tau231, exhibited the highest fold-changes in AD cases compared with non-AD cases, greater than the other p-tau (181, 199, 202) and non-phosphorylated tau (195–209, 212–221).